CGM for Insulin-Treated T2DM During Post-Discharge Transition

Inclusion criteria

• Age 18 to 80 years (inclusive).
• Confirmed diagnosis of type 2 diabetes mellitus (T2DM).
• HbA1c between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening/enrollment.
• Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed/confirmed by the treating physician (principal physician).

Exclusion criteria

• Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment.
• Severe skin disease at the sensor insertion site, or allergy to adhesive tape/adhesives.
• Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period.
• Currently participating in, or planning to participate in, another clinical trial.
• Current use of oral corticosteroid therapy, or anticipated use during the trial period.
• Severe liver disease, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN).
• Severe renal impairment or end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m².
• Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand/comply due to speech/language impairment; or presence of psychiatric disorders.